<DOC>
	<DOCNO>NCT00565539</DOCNO>
	<brief_summary>Interleukin 29 ( IL-29 ) substance produce body help fight viral infection . The purpose study test safety antiviral effect PEG-rIL-29 ( man-made form IL-29 ) give either different dos combination approve dose ribavirin ( antiviral drug ) subject hepatitis C infection receive prior treatment disease relapse follow previous treatment PEGylated interferon alpha ( PEG-IFN-α ) , form IFN-α , ribavirin .</brief_summary>
	<brief_title>Study PEG-rIL-29 ( PEG-IFN Lambda ) Subjects With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description>This 3-part study PEG-rIL-29 subject chronic genotype 1 hepatitis C virus infection either receive prior treatment PEGylated IFN-α ( form IFN-α ) relapse follow prior treatment PEGylated IFN-α ( form IFN-α ) ribavirin . Part 1 study evaluate safety tolerability escalate dos PEG-rIL-29 give single agent either every week weekly 4-week period treatment-relapsed subject . Part 2 study evaluate dose level and/or schedule PEG-rIL-29 combination daily oral ribavirin administer 4-week period treatment-relapsed subject . Part 3 study evaluate dose level and/or schedule PEG-rIL-29 combination daily oral ribavirin administer 4-week period subject receive prior treatment .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Relapsed subject ( Parts 1 2 ) Prior treatment HCV PEGIFNalpha ( IFNalpha ) ribavirin least 12 week . Naive subject ( Part 3 ) No prior treatment PEGIFNalpha ( IFNalpha ) Genotype 1 HCV RNA great equal 100,000 IU/mL . Mixed genotype HCV infection allow Documented liver biopsy ≤2 year study enrollment Ishak score ≤4 No evidence hepatocellular carcinoma document abdominal imaging within 12 month study entry evidence clinically significant diastolic systolic dysfunction clinically significant abnormality echocardiogram ECG Negative drug alcohol test except physician prescribed approve medication If male , female childbearing potential , agree use 2 form medically accept contraception study Evidence decompensated liver disease History hypersensitivity IFNalpha ribavirin Active substance abuse , alcohol , inhale injection drug within previous 6 month Undergone surgery receive blood product within 30 day prior study enrollment Prior history cardiomyopathy , coronary artery disease include angina , interventive procedure coronary artery disease include angioplasty , stent procedure cardiac bypass surgery , prior myocardial infarction , ventricular tachycardia Prior current history hemoglobinopathy hemolytic anemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>PEGylated recombinant interleukin 29</keyword>
	<keyword>interferon lambda</keyword>
	<keyword>interleukin 29</keyword>
	<keyword>hepatitis C</keyword>
	<keyword>virus</keyword>
	<keyword>infection</keyword>
	<keyword>liver</keyword>
</DOC>